Advertisement

Reactions Weekly

, Volume 1753, Issue 1, pp 17–17 | Cite as

Afatinib/gefitinib

Interstitial lung disease and pneumonitis: 2 case reports
Case report
  • 16 Downloads

Reference

  1. Kim Y, et al. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Research and Treatment 51: 502-509, No. 2, Jan 2019. Available from: URL: http://doi.org/10.4143/crt.2018.117 - South Korea

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations